Investigational Drug Details
| Drug ID: | D587 |
| Drug Name: | Fecal microbiota transplantation |
| Synonyms: | FMT |
| Type: | Miscellany |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00181 | 35195774 | Arch Microbiol | A review on the effect of gut microbiota on metabolic diseases. | Details |
| A00384 | 35108315 | PLoS One | Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | Details |
| A00955 | 34920070 | Int J Biol Macromol | MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. | Details |
| A01187 | 34835981 | Nutrients | Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice. | Details |
| A01368 | 34773257 | Hepatology | A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. | Details |
| A01474 | 34734433 | J Gastroenterol Hepatol | New perspective on fecal microbiota transplantation in liver diseases. | Details |
| A01475 | 34734369 | J Gastrointest Surg | The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. | Details |
| A01838 | 34598315 | Immun Inflamm Dis | Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. | Details |
| A01945 | 34557498 | Front Med (Lausanne) | Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. | Details |
| A02176 | 34473644 | Aging (Albany NY) | Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. | Details |
| A02186 | 34469716 | Cell Rep | Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. | Details |
| A02259 | 34444932 | Nutrients | The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. | Details |
| A02359 | 34403877 | Phytomedicine | A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. | Details |
| A02865 | 34212214 | Inflamm Res | Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. | Details |
| A02892 | 34204274 | Int J Mol Sci | Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. | Details |
| A03134 | 34118321 | Gastroenterol Hepatol | Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. | Details |
| A03453 | 33994854 | Int J Biol Sci | Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. | Details |
| A03556 | 33957682 | Semin Liver Dis | New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. | Details |
| A03731 | 33887125 | United European Gastroenterol J | Gut fermentation syndrome: A systematic review of case reports. | Details |